--- title: "Enclomiphene: Dosing & Vendor Prices | BodyHackGuide" url: https://www.bodyhackguide.co/compound/enclomiphene description: "Enclomiphene: dosing protocols, mechanism & side effects, 95 PubMed results. Compare 2 current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: Enclomiphene molecular structure (https://www.bodyhackguide.co/assets/peptide-structure-placeholder-DUmZBF_j.png) # Enclomiphene Hormone Support (https://www.bodyhackguide.co/wiki#cat-hormone-support)Phase III Also known as: Androxal Enclomiphene citrate (ENC, Androxal, trans-clomiphene) is the pure trans-isomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM) developed originally by Repros Therapeutics for the treatment of secondary (hypogonadotropic) hypogonadism in men who want to preserve fertility. Where clomiphene citrate — the classical ovulation induction drug used in women since FDA approval in 1967 — is a 62:38 mixture of two geometric isomers (enclomiphene and zuclomiphene), enclomiphene is the short-acting antagonist component that carries virtually all of the therapeutically useful activity at the male hypothalamic-pituitary-gonadal (HPG) axis, while zuclomiphene is a long-half-life weak estrogen agonist that accumulates with chronic dosing and is blamed for much of clomiphene's off-target visual, mood, and gynecomastia-risk profile. In men, enclomiphene works by competitively blocking estradiol at estrogen receptor alpha (ERα) in the hypothalamus and pituitary. Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Lowest price per mg $0.213/mg $79.99 for 375mg at Disguised Alpha · Buy at Disguised Alpha: https://disguisedalpha.com/product/enclomipheneliquid/?coupon=reddit Half-life: ~10 hours Route: Oral MW: 405.9 Da CAS: 15690-57-0 95 PubMed results (https://pubmed.ncbi.nlm.nih.gov/?term=enclomiphene%20citrate) Last reviewed: May 4, 2026 ## Overview ### At A Glance Mechanism Primary Mechanism: Central Estrogen Receptor Antagonism… Half-Life ~10 hours Dosing Once daily oral Dose Range 6,250–25,000 mcg (6.25–25 mg) oral daily Routes Oral Common Vials 12.5mg capsules 25mg capsules Potential Benefits Increased endogenous testosterone production HPTA axis restoration after suppression Maintained fertility during TRT Improved LH and FSH levels Fewer estrogenic side effects than clomiphene ### Mechanism of Action ### Primary Mechanism: Central Estrogen Receptor Antagonism Enclomiphene is a non-steroidal triphenylethylene with a molecular structure closely related to tamoxifen. Pharmacologically, it behaves as a mixed agonist/antagonist at estrogen receptors — a classical SERM profile — but with tissue-specific effects that differ markedly from tamoxifen, raloxifene, and other SERMs used in oncology and osteoporosis. At the hypothalamus and anterior pituitary, enclomiphene is a **pure antagonist** of estrogen receptor alpha (ERα). Under physiological conditions, circulating estradiol (E2) — most of which is produced in men via peripheral aromatization of testosterone in adipose tissue, liver, and skin — binds hypothalamic ERα and provides the major negative feedback signal that throttles GnRH pulse generation. This feedback loop is the biological governor on the HPG axis: as testosterone rises, aromatization generates estradiol, estradiol suppresses GnRH, and LH/FSH output falls, completing the circuit. When enclomiphene occupies hypothalamic ERα, estradiol can no longer exert this suppressive feedback. The hypothalamus perceives the estrogen signal as absent and responds by: 1. **Increasing GnRH pulse frequency**: Kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus (AVPV) are derepressed, leading to more frequent GnRH bursts ([Dwyer et al., 2015]). 2. **Amplifying pituitary gonadotroph response**: The pituitary becomes more sensitive to GnRH stimulation, producing larger LH and FSH pulses per GnRH input. 3. **Driving downstream testicular steroidogenesis**: LH stimulates Leydig cells to synthesize testosterone from cholesterol via the classical steroidogenic pathway (StAR → P450scc → 3β-HSD → CYP17 → 17β-HSD). FSH supports Sertoli cell function and spermatogenesis. The net effect is an upward shift in the entire HPG axis set point — higher LH, higher FSH, and higher endogenous testosterone — without exogenous hormone administration. In clinical studies, typical LH increases range from 2-4x baseline, testosterone rises 50-100% from hypogonadal baseline, and the effects are maintained with chronic dosing because enclomiphene does not accumulate or cause tachyphylaxis ([Kaminetsky et al., 2013]). ### The Enclomiphene vs. Zuclomiphene Distinction Clomiphene citrate as prescribed for female ovulation induction is a racemic mixture of two stereoisomers: enclomiphene (the E-isomer, ~62%) and zuclomiphene (the Z-isomer, ~38%). These two molecules differ only in the geometric orientation around a single double bond, but their pharmacology is dramatically different: - **Enclomiphene** is a short-acting ERα antagonist with a half-life of approximately 10 hours and complete clearance within 1-2 weeks of discontinuation. It does NOT accumulate with chronic dosing. - **Zuclomiphene** is a long-acting weak ERα agonist with a half-life of 30+ days and measurable tissue concentrations for months after stopping chronic therapy. It DOES accumulate. This distinction matters enormously for men. When men take clomiphene long-term (the common "clomid TRT" approach), zuclomiphene gradually accumulates and begins to produce estrogen-agonist effects: visual disturbances (shimmering, floaters, rarely permanent retinal changes), mood destabilization (depression, anxiety, emotional lability), libido suppression paradoxically overriding the testosterone boost, and potentially long-term safety concerns from chronic ERα agonism in a male. Many of the complaints men have about "clomid" — the mood crashes, the vision issues, the libido problems — are attributable to zuclomiphene rather than to the antagonist component. Purifying enclomiphene removes zuclomiphene entirely. The result is a cleaner molecule that delivers the HPG axis stimulation without the off-target agonist burden. In head-to-head comparisons and clinical trials, enclomiphene produces substantially fewer mood, visual, and libido side effects than equipotent doses of clomiphene ([Wiehle et al., 2013]). This is the central pharmacological argument for using enclomiphene rather than clomiphene for extended HPG axis support. ### Fertility Preservation Pharmacology The clinical feature that sets enclomiphene apart from exogenous testosterone is its effect on spermatogenesis. Exogenous testosterone (whether injectable, topical, or oral) suppresses LH and FSH via direct pituitary negative feedback after peripheral conversion to estradiol and via direct androgen receptor feedback in the hypothalamus. This suppression drops intratesticular testosterone concentrations from their normal range of 500-1,000 ng/mL down to serum levels (5-10 ng/mL) — a 50-100x decrease. Since spermatogenesis requires extraordinarily high local testosterone concentrations (20-100x serum levels) to proceed through meiosis, the result is progressive oligospermia and, in most men, frank azoospermia within 3-6 months of consistent TRT use. Enclomiphene has the opposite effect. By stimulating rather than suppressing the HPG axis, it drives LH to support intratesticular testosterone production AND drives FSH to support Sertoli cell function and spermatogenesis directly. In men with baseline sub-fertility from secondary hypogonadism, enclomiphene typically improves sperm concentration, motility, and total motile count over 3-6 months of therapy ([Shabsigh et al., 2005] on clomiphene, with analogous data for enclomiphene). For men who want both symptomatic relief from low testosterone AND preservation of reproductive potential, this is a substantial advantage over TRT. ### Hepatic Metabolism and Pharmacokinetics Enclomiphene is orally bioavailable with peak plasma concentrations reached 4-8 hours after dosing. It undergoes extensive first-pass hepatic metabolism primarily via CYP2D6 and CYP3A4, with the main metabolite 4-hydroxy-enclomiphene retaining some antiestrogenic activity. Terminal elimination half-life is approximately 10 hours, which is why once-daily dosing is adequate for stable LH/FSH elevation. Excretion is primarily biliary/fecal, with minor urinary elimination. Because of CYP2D6 involvement, men who are CYP2D6 poor metabolizers (~7% of Caucasians, ~2% of East Asians) may experience higher plasma concentrations and more pronounced effects at standard doses. CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) may also elevate enclomiphene levels modestly, though clinically significant interactions are uncommon. CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) may reduce enclomiphene plasma levels and blunt response. ### Off-Target Receptor Activity Relative to tamoxifen and other SERMs, enclomiphene has minimal off-target activity at estrogen receptor beta (ERβ), androgen receptor, progesterone receptor, or glucocorticoid receptor. This relatively clean receptor profile contributes to its favorable tolerability in men, as most SERM-related side effects (hot flashes with tamoxifen, endometrial effects, bone density changes) arise from tissue-specific agonism at ERα in organs outside the HPG axis. Enclomiphene appears to be a near-pure HPG-axis modulator with minimal extra-axis activity at therapeutic doses. ### Overview Enclomiphene citrate (ENC, Androxal, trans-clomiphene) is the pure trans-isomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM) developed originally by Repros Therapeutics for the treatment of secondary (hypogonadotropic) hypogonadism in men who want to preserve fertility. Where clomiphene citrate — the classical ovulation induction drug used in women since FDA approval in 1967 — is a 62:38 mixture of two geometric isomers (enclomiphene and zuclomiphene), enclomiphene is the short-acting antagonist component that carries virtually all of the therapeutically useful activity at the male hypothalamic-pituitary-gonadal (HPG) axis, while zuclomiphene is a long-half-life weak estrogen agonist that accumulates with chronic dosing and is blamed for much of clomiphene's off-target visual, mood, and gynecomastia-risk profile. In men, enclomiphene works by competitively blocking estradiol at estrogen receptor alpha (ERα) in the hypothalamus and pituitary. Negative feedback from circulating estradiol normally throttles gonadotropin-releasing hormone (GnRH) pulse generation; when enclomiphene occupies these receptors, the hypothalamus is "blinded" to estrogen, GnRH pulse frequency increases, the pituitary ramps up luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, and the testes respond by increasing endogenous testosterone production and spermatogenesis. The net clinical effect, in men with a functional HPG axis that is simply being under-driven (secondary hypogonadism), is a restoration of serum total testosterone into the mid-normal range — often 500-700 ng/dL from baselines below 300 ng/dL — while preserving or improving sperm count, motility, and morphology. This stands in sharp contrast to exogenous testosterone replacement therapy (TRT), which suppresses LH/FSH, shuts down intratesticular testosterone production, and typically drives sperm counts toward azoospermia within 3-6 months of use ([Anawalt, 2020]). Enclomiphene sits in an unusual regulatory limbo. Repros Therapeutics ran two successful Phase 3 trials (ZA-301 and ZA-302) in overweight men with secondary hypogonadism, demonstrating that once-daily 12.5 mg or 25 mg enclomiphene restored morning total testosterone while maintaining or increasing sperm concentration relative to both placebo and topical testosterone gel ([Kim et al., 2016]). Despite these results, the FDA declined to approve Androxal in 2015, citing concerns about the clinical meaningfulness of the primary endpoints and the absence of long-term cardiovascular outcomes data — concerns that parallel the broader regulatory pushback against all low-T treatment paradigms during the 2013-2016 era. Repros subsequently went bankrupt, and the molecule fell into a commercial gray zone: not FDA-approved, but sold widely through US telehealth clinics and compounding pharmacies under state physician supervision as an "off-label" or "investigational" testosterone tuning tool, particularly for men who want to avoid the fertility penalty of TRT. For bodybuilders, biohackers, and men pursuing testosterone tuning, enclomiphene has become a central pillar of the "fertility-preserving" and "post-cycle therapy" toolkits. It is used as (1) a monotherapy for men with secondary hypogonadism who want natural production rather than exogenous testosterone; (2) a post-cycle therapy (PCT) agent after anabolic steroid cycles to restart the HPG axis; (3) an adjunct or alternative to hCG (https://www.bodyhackguide.co/compound/hcg) for men on TRT who want to preserve testicular volume and fertility; and (4) a mild endogenous testosterone booster in men with borderline hypogonadism or age-related T decline. Its oral dosing, lack of injection requirement, favorable side effect profile relative to clomiphene itself, and fertility-preserving mechanism make it one of the more popular prescription-gray-market molecules in the men's health tuning space. This entry covers the full pharmacology, clinical evidence base, protocol considerations, and safety profile of enclomiphene citrate. It is intended for educational and research reference only — enclomiphene is a prescription drug in most jurisdictions, is NOT FDA-approved for any indication, and the decision to use it should involve a qualified physician who can order appropriate baseline and follow-up labs (total testosterone, free testosterone, estradiol, LH, FSH, SHBG, CBC, CMP, lipid panel, and semen analysis when fertility is a concern). Cross-reference this page with HCG (https://www.bodyhackguide.co/compound/hcg), Gonadorelin (https://www.bodyhackguide.co/compound/gonadorelin), and Kisspeptin-10 (https://www.bodyhackguide.co/compound/kisspeptin-10) for a complete picture of HPG axis modulation strategies. ## Chemical Information IUPAC Name (E)-2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl-ethanamine CAS Number 15690-57-0 Molecular Formula C26H28ClNO Molecular Mass 405.96 g/mol Image: Enclomiphene molecular structure (https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/1548953/PNG) View on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/1548953 ## Dosing & Protocols ### Unlock the dosing protocols Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser. - Dose, route, how often and how long - Beginner, intermediate and advanced protocols - Reconstitution and handling notes - Stacking notes You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) ## Research ### Unlock the research summary - A summary of the key research - Safety and side effects - A link to the PubMed results ## Interactions ### Interaction Matrix ### Contraindications ### Absolute Contraindications Enclomiphene must NOT be used in the following conditions: - **Known hypersensitivity to enclomiphene, clomiphene, or other triphenylethylene SERMs** — cross-reactivity possible - **Pregnancy** — enclomiphene is not intended for use in women, and would be strongly contraindicated if pregnancy were somehow involved; category X analog equivalent - **Current or history of thromboembolic disease** — deep vein thrombosis, pulmonary embolism, stroke. SERM class carries theoretical and some empirical VTE risk. - **Known thrombophilia** — Factor V Leiden, prothrombin gene mutation, protein C/S deficiency, antithrombin deficiency. Elevated baseline VTE risk may be further increased by SERM therapy. - **Active or recent myocardial infarction** — especially within 6 months - **Uncontrolled heart failure** — NYHA Class III-IV or decompensated disease - **Severe hepatic impairment** — Child-Pugh Class C; metabolism will be impaired and hepatotoxicity risk elevated - **Untreated pituitary adenoma or mass lesion** — enclomiphene assumes intact pituitary function; macroadenomas should be identified and addressed first - **Primary (testicular) hypogonadism with maximally elevated LH** — enclomiphene cannot work when the testes themselves are the limiting factor and LH is already maximally stimulated - **Men seeking contraception or attempting NOT to preserve fertility** — enclomiphene enhances rather than suppresses fertility; if fertility preservation is specifically undesired (e.g., due to genetic disease concerns), TRT may be preferable ### Relative Contraindications / Use with Extreme Caution - **Moderate hepatic impairment** (Child-Pugh Class A-B): Reduce dose, monitor LFTs more frequently - **Moderate cardiovascular disease** (stable angina, prior MI >6 months ago, controlled heart failure): Case-by-case assessment, stricter monitoring - **Prior VTE risk factors** (prolonged immobilization planned, active malignancy, advanced age, combined HRT use): Assess individual risk - **History of mood disorders**: Screen carefully, monitor closely, consider dose adjustments; some men have significant mood effects even on enclomiphene - **Visual disorders or prior issues with clomiphene**: Watch carefully for visual symptoms; may still be usable at lower doses - **Erythrocytosis or pre-existing elevated hematocrit**: Higher baseline risk of supra-physiologic hematocrit with T elevation; frequent monitoring - **Prostate disease**: Baseline and follow-up PSA; BPH may worsen with androgen elevation; known prostate cancer is controversial but generally contraindicated - **Polycystic ovarian syndrome or hormonal disorders in partners**: Not a contraindication for the male user, but worth noting for fertility planning - **Concurrent CYP2D6 inhibitors or inducers**: Monitor for over/under-response; titrate cautiously ### Specific Drug Interactions - **SSRIs/SNRIs** (fluoxetine, paroxetine, duloxetine): CYP2D6 inhibition may elevate enclomiphene; also potential additive mood effects - **Bupropion**: CYP2D6 inhibition; additive mood monitoring - **Warfarin and anticoagulants**: SERM class may increase INR and bleeding risk; monitor more frequently; generally not combined unless necessary - **Tamoxifen**: Combining two SERMs is rarely appropriate; if clinically indicated, close specialist supervision required - **Raloxifene**: Similar overlap concerns; use one SERM at a time - **Letrozole, anastrozole, exemestane** (AIs): Combination is rational for estradiol management but requires careful dose titration to avoid E2 crash - **Testosterone**: Concurrent use is debated; clinicians using this combination should document rationale - **hCG**: Combination is useful and well-tolerated for HPG axis optimization - **GnRH analogs** (leuprolide, goserelin): Pharmacologically opposing; don't combine - **Hormonal contraceptives or cyclic progestins**: Not applicable to male users; female partners using these have no interaction concern - **Thyroid medications**: No direct interaction; ensure thyroid status optimized independently - **Kratom, opioids**: Chronic opioid use suppresses HPG axis directly and may mask enclomiphene benefit; consider opioid status in evaluation ### Lifestyle and Supplement Interactions - **Alcohol**: Heavy alcohol use impairs HPG axis independently, causes hepatic stress relevant to drug metabolism, may negate clinical benefit. Moderate (<7 drinks/week) generally fine. - **Grapefruit juice**: CYP3A4 inhibition; may elevate enclomiphene levels. Avoid excessive intake. - **St. John's wort**: Strong CYP3A4 inducer; may reduce enclomiphene levels. Avoid concurrent use. - **Anabolic steroids or SARMs**: Masks HPG axis status and defeats purpose of enclomiphene therapy. Disclose all use to prescribing clinician. - **Soy isoflavones (high-dose supplements)**: Weak ERα agonists; theoretical interaction. Dietary soy is not a concern. - **DHEA, pregnenolone, androstenedione**: Hormonal precursors; may confound lab interpretation and HPG axis assessment. Discuss with clinician. ### Pre-Treatment Workup Requirements Before initiating enclomiphene, ensure: 1. Two separate morning fasting testosterone measurements confirming low T 2. LH and FSH confirming secondary (or mixed) hypogonadism pattern 3. Prolactin within normal range, OR worked up and treated 4. Thyroid function optimized 5. Age-appropriate prostate screening (PSA if >40) 6. Baseline hematocrit, lipids, LFTs 7. Assessment for sleep apnea (treats secondary hypogonadism without drugs if present) 8. Medication review for confounding agents (chronic opioids, cannabis in some users, certain psychiatric medications) 9. Weight and lifestyle assessment — weight loss alone may resolve secondary hypogonadism in obese men 10. Pituitary evaluation if clinical concern (visual field issues, other pituitary hormone abnormalities, structural symptoms) ### Monitoring for Adverse Response - Any visual symptom: discontinue, ophthalmology referral - Mood destabilization beyond mild: reassess continuation - Signs of VTE (leg pain/swelling, chest pain, dyspnea): immediate emergency evaluation - Jaundice, dark urine, severe abdominal pain: immediate LFT check - Severe headache unresponsive to conservative measures: discontinue, neurology evaluation - Chest pain, dyspnea, leg edema: cardiology evaluation ### Pregnancy and Lactation Enclomiphene is not indicated in women or during pregnancy. Male use does not affect female partners directly, but if fertility success results in pregnancy, no continued exposure to enclomiphene for the pregnant partner occurs or is relevant. ### Pediatric Use Not indicated in pediatric populations. Adolescent hypogonadism requires pediatric endocrinology specialist evaluation. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $59.99 up to $119.99 Best $/mg $0.2133 Vendors 2 Listings 3 capsule, liquid Form Sort | Vendor | Product | Form | Qty | Price | $/mg | Coupon | | | --- | --- | --- | --- | --- | --- | --- | --- | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | Liquid Enclomiphene 12.5 mg/mL | liquid | 30 mL (12.5 mg/mL) ● In Stock | $79.99 VALUE | $0.213 | — | Buy: https://disguisedalpha.com/product/enclomipheneliquid/?coupon=reddit | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | Enclomiphene Citrate Capsules | capsule | capsules ● In Stock | $119.99 | — | — | Buy: https://disguisedalpha.com/product/enclomiphene/?coupon=reddit | | Image: VANDL Labs logo (https://halfnattys.shop/wp-content/themes/halfnattys/assets/img/logo.webp) VANDL Labs (https://www.bodyhackguide.co/vendors/vandl-labs) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | Enclomiphene Capsules 60ct | capsule | 60 capsules ● In Stock | $59.99 BEST | — | CHON | Buy: https://www.vandl-labs.com/product/enclomiphene-capsules/?ref=choncho | ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Enclomiphene. Current low $59.99 current listings 7-day low — not enough history yet 30-day low — not enough history yet 30-day change — not enough history yet Tracking since Apr 6, 2026 · 3 data points ## Price History 2 data points ### Vendors Selling Enclomiphene #### VANDL Labs 1 listing · from $59.99 https://www.bodyhackguide.co/vendors/vandl-labs #### Disguised Alpha 2 listings · from $79.99 https://www.bodyhackguide.co/vendors/disguised-alpha How we score these vendors Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. View Scorecard (https://www.bodyhackguide.co/vendors/scorecard) ### Related Compounds View All (https://www.bodyhackguide.co/wiki) ### T3/T4 Thyroid Blend Hormone Support Components are FDA-approved prescription drugs (levothyroxine and liothyronine); the fixed-ratio synthetic T3/T4 combination product is investigational/unapproved as sold and is framed here strictly for research use only (RUO). A T3/T4 blend pairs two real, FDA-approved thyroid hormones - levothyroxine (T4) and liothyronine (T3) - in a single product, intended to more closely mimic the thyroid gland's natural output than T4 alone. t½ T4 (levothyroxine): approximately 6-7 days in euthyroid adults (longer in hypothyroid, shorter in hyperthyroid states). T3 (liothyronine): approximately 1 day (~18-24 hours), which is why T3 is dosed multiple times daily or as a slow-release preparation. Component-split and physician-set, not a fixed self-dose: T4 (levothyroxine) approximately 75-150 mcg/day and T3 (liothyronine) approximately 5-20 mcg/day divided - both titrated to labs (TSH, free T4, free T3), individualized by weight, age and cardiac status. Not a self-dosing recommendation. Preclinical View Profile https://www.bodyhackguide.co/compound/t3-t4-blend View Full Dosage Guide → Protocols, calculator & safety for Enclomiphene https://www.bodyhackguide.co/guides/dosage/enclomiphene ### Lowest Price per mg Disguised Alpha $79.99($0.213/mg) 2 vendors · 3 listings ### Research Score 40 95 PubMed results ### Quality Indicators Data Completeness 100% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings Research Volume 95 PubMed results Well-researched compound ### Quick Facts Half-Life ~10 hours Molecular Weight 405.96 g/mol Administration Oral CAS Number 15690-57-0 Trial Phase Phase III 0 Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions How is enclomiphene different from clomiphene (Clomid)? Clomiphene citrate (Clomid) is a 62:38 mixture of two stereoisomers: enclomiphene (the antagonist component) and zuclomiphene (a weak long-acting agonist). Enclomiphene is the purified antagonist alone, without zuclomiphene. Because zuclomiphene has a ~30-day half-life and accumulates with chronic dosing — producing most of clomiphene's mood, visual, and libido side effects — enclomiphene offers a cleaner tolerability profile while preserving the HPG axis stimulation that raises testosterone and LH/FSH (Wiehle et al., 2013 (https://pubmed.ncbi.nlm.nih.gov/23714402/)). Is enclomiphene FDA-approved? No. Repros Therapeutics developed enclomiphene as 'Androxal' and completed successful Phase 3 trials, but the FDA issued a Complete Response Letter in 2015 declining approval and citing concerns about the clinical meaningfulness of primary endpoints and long-term cardiovascular safety data. Repros went bankrupt in 2017. Enclomiphene remains available through US compounding pharmacies with physician prescription as an 'off-label' or investigational medication, typically in men's health clinic settings. Does enclomiphene preserve fertility compared to testosterone replacement? Yes, this is the central clinical advantage. Exogenous testosterone suppresses LH and FSH, which dramatically reduces intratesticular testosterone and typically produces oligospermia or azoospermia within 3-6 months. Enclomiphene does the opposite — it stimulates LH/FSH, which drives both endogenous testosterone and spermatogenesis. In the Phase 3 Repros trials, enclomiphene groups maintained or improved sperm concentration while testosterone gel reduced it by approximately 40% (Kim et al., 2016 (https://pubmed.ncbi.nlm.nih.gov/26873583/)). What dose should I start with? 12.5 mg once daily is the standard starting dose for men with secondary hypogonadism. Most men reach adequate testosterone normalization (500-800 ng/dL) at this dose within 4-6 weeks. If response is partial after 8-12 weeks, increasing to 25 mg daily is reasonable. Higher doses (50+ mg) are generally reserved for short-course PCT applications and increase side effects substantially. Always obtain baseline labs and work with a physician. How long does it take to see results? LH and FSH typically rise within the first week. Testosterone begins climbing noticeably by weeks 2-3 and approaches steady-state by weeks 6-8. Subjective symptom improvements (energy, libido, mood) often follow the hormonal changes with a 2-4 week lag — many men notice them by weeks 4-8. Sperm parameter changes, if present, take longer (3-6 months typically), reflecting the spermatogenesis cycle duration. Can I take enclomiphene long-term? Yes, enclomiphene can be continued indefinitely if tolerated and effective, based on clinical experience — there is no evidence of tachyphylaxis (loss of effect) over at least 12 months of continuous therapy, and it does not accumulate. Most long-term users settle on 12.5 mg daily or every-other-day maintenance dosing. Periodic reassessment (every 6-12 months) of ongoing need, response, and safety labs is recommended. Unlike TRT, stopping enclomiphene does not cause a dramatic hormonal crash. What side effects are most common? The most common side effects are headache (8-12%), nausea (6-9%), hot flashes (5-8%), mild acne (4-7%), and mild mood changes (3-6%). Visual disturbances (shimmering, floaters) occur in less than 2% but should always prompt immediate discontinuation if noticed. Most side effects are mild, occur early in therapy, and resolve with continued use or dose adjustment. Enclomiphene is substantially better tolerated than clomiphene for equivalent HPG axis effect. Can enclomiphene be used for post-cycle therapy (PCT)? Yes, enclomiphene is a standard PCT agent, often used at 25 mg daily for 4 weeks followed by 12.5 mg daily for 2-4 weeks. Advanced PCT protocols combine hCG (to restart testicular responsiveness) with enclomiphene plus optionally tamoxifen. PCT effectiveness depends on cycle duration, compound used, and individual HPG axis resilience. Some men recover fully; others require extended support or ultimately transition to TRT. Always baseline and follow-up labs to confirm recovery. How does enclomiphene compare to hCG for preserving fertility on TRT? Both can preserve testicular function and fertility alongside TRT, but mechanistically differ. hCG directly mimics LH and stimulates Leydig cells to produce intratesticular testosterone — bypassing the hypothalamus entirely. Enclomiphene blocks estrogen receptors centrally, increasing endogenous LH/FSH. On TRT, exogenous testosterone suppresses this central signaling, making enclomiphene less effective — hCG is the more conventional choice for TRT-alongside fertility preservation. Enclomiphene is best as a monotherapy (replacing TRT) rather than an adjunct. What labs should I monitor on enclomiphene? Baseline: total testosterone, free testosterone, estradiol (sensitive LC/MS assay), LH, FSH, SHBG, prolactin, TSH, CBC, CMP, lipid panel, PSA if age >40, semen analysis if fertility relevant. Follow-up labs at 4-6 weeks after starting or dose changes, then every 3-6 months once stable, then every 6-12 months for long-term maintenance. Target ranges: total T 500-800 ng/dL, estradiol 20-40 pg/mL, hematocrit <52%, LH typically 2-4x baseline confirming mechanistic response. ## Research Tools ### Peptide Calculator Reconstitution & syringe units https://www.bodyhackguide.co/tools/reconstitution ### Reconstitution Guide How to mix, step by step https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides ### Nasal Spray Calc mL per actuation https://www.bodyhackguide.co/tools/intranasal ### Half-Life Visualizer Decay curves https://www.bodyhackguide.co/tools/halflife ## Related Compounds ### T3/T4 Thyroid Blend Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Enclomiphene" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Enclomiphene", "description": "Enclomiphene citrate (ENC, Androxal, trans-clomiphene) is the pure trans-isomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM) developed originally by Repros Therapeutics for the treatment of secondary (hypogonadotropic) hypogonadism in men who want to preserve fertility. Where clomiphene citrate — the classical ovulation induction drug used in women since FDA approval in 1967 — is a 62:38 mixture of two geometric isomers (enclomiphene and zuclomiphene), enclomiphene is the short-acting antagonist component that carries virtually all of the therapeutically useful activity at the male hypothalamic-pituitary-gonadal (HPG) axis, while zuclomiphene is a long-half-life weak estrogen agonist that accumulates with chronic dosing and is blamed for much of clomiphene's off-target visual, mood, and gynecomastia-risk profile. In men, enclomiphene works by competitively blocking estradiol at estrogen receptor alpha (ERα) in the hypothalamus and pituitary. Negative feedback from circulating estradiol normally throttles gonadotropin-releasing hormone (GnRH) pulse generation; when enclomiphene occupies these receptors, the hypothalamus is \"blinded\" to estrogen, GnRH pulse frequency increases, the pituitary ramps up luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, and the testes respond by increasing endogenous testosterone production and spermatogenesis. The net clinical effect, in men with a functional HPG axis that is simply being under-driven (secondary hypogonadism), is a restoration of serum total testosterone into the mid-normal range — often 500-700 ng/dL from baselines below 300 ng/dL — while preserving or improving sperm count, motility, and morphology. This stands in sharp contrast to exogenous testosterone replacement therapy (TRT), which suppresses LH/FSH, shuts down intratesticular testosterone production, and typically drives sperm counts toward azoospermia within 3-6 months of use ([Anawalt, 2020]). Enclomiphene sits in an unusual regulatory limbo. Repros Therapeutics ran two successful Phase 3 trials (ZA-301 and ZA-302) in overweight men with secondary hypogonadism, demonstrating that once-daily 12.5 mg or 25 mg enclomiphene restored morning total testosterone while maintaining or increasing sperm concentration relative to both placebo and topical testosterone gel ([Kim et al., 2016]). Despite these results, the FDA declined to approve Androxal in 2015, citing concerns about the clinical meaningfulness of the primary endpoints and the absence of long-term cardiovascular outcomes data — concerns that parallel the broader regulatory pushback against all low-T treatment paradigms during the 2013-2016 era. Repros subsequently went bankrupt, and the molecule fell into a commercial gray zone: not FDA-approved, but sold widely through US telehealth clinics and compounding pharmacies under state physician supervision as an \"off-label\" or \"investigational\" testosterone tuning tool, particularly for men who want to avoid the fertility penalty of TRT. For bodybuilders, biohackers, and men pursuing testosterone tuning, enclomiphene has become a central pillar of the \"fertility-preserving\" and \"post-cycle therapy\" toolkits. It is used as (1) a monotherapy for men with secondary hypogonadism who want natural production rather than exogenous testosterone; (2) a post-cycle therapy (PCT) agent after anabolic steroid cycles to restart the HPG axis; (3) an adjunct or alternative to hCG for men on TRT who want to preserve testicular volume and fertility; and (4) a mild endogenous testosterone booster in men with borderline hypogonadism or age-related T decline. Its oral dosing, lack of injection requirement, favorable side effect profile relative to clomiphene itself, and fertility-preserving mechanism make it one of the more popular prescription-gray-market molecules in the men's health tuning space. This entry covers the full pharmacology, clinical evidence base, protocol considerations, and safety profile of enclomiphene citrate. It is intended for educational and research reference only — enclomiphene is a prescription drug in most jurisdictions, is NOT FDA-approved for any indication, and the decision to use it should involve a qualified physician who can order appropriate baseline and follow-up labs (total testosterone, free testosterone, estradiol, LH, FSH, SHBG, CBC, CMP, lipid panel, and semen analysis when fertility is a concern). Cross-reference this page with HCG, Gonadorelin, and Kisspeptin-10 for a complete picture of HPG axis modulation strategies.", "url": "https://www.bodyhackguide.co/compound/enclomiphene", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "59.99", "highPrice": "119.99", "priceCurrency": "USD", "offerCount": "3", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "59.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.vandl-labs.com/product/enclomiphene-capsules/?ref=choncho", "seller": { "@type": "Organization", "name": "VANDL Labs", "url": "https://www.vandl-labs.com/?ref=choncho" } }, { "@type": "Offer", "price": "79.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/enclomipheneliquid/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "Enclomiphene 375mg liquid" }, { "@type": "Offer", "price": "119.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/enclomiphene/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Enclomiphene", "description": "Enclomiphene citrate (ENC, Androxal, trans-clomiphene) is the pure trans-isomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM) developed originally by Repros Therapeutics for the treatment of secondary (hypogonadotropic) hypogonadism in men who want to preserve fertility. Where clomiphene citrate — the classical ovulation induction drug used in women since FDA approval in 1967 — is a 62:38 mixture of two geometric isomers (enclomiphene and zuclomiphene), enclomiphene is the short-acting antagonist component that carries virtually all of the therapeutically useful activity at the male hypothalamic-pituitary-gonadal (HPG) axis, while zuclomiphene is a long-half-life weak estrogen agonist that accumulates with chronic dosing and is blamed for much of clomiphene's off-target visual, mood, and gynecomastia-risk profile. In men, enclomiphene works by competitively blocking estradiol at estrogen receptor alpha (ERα) in the hypothalamus and pituitary. Negative feedback from circulating estradiol normally throttles gonadotropin-releasing hormone (GnRH) pulse generation; when enclomiphene occupies these receptors, the hypothalamus is \"blinded\" to estrogen, GnRH pulse frequency increases, the pituitary ramps up luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, and the testes respond by increasing endogenous testosterone production and spermatogenesis. The net clinical effect, in men with a functional HPG axis that is simply being under-driven (secondary hypogonadism), is a restoration of serum total testosterone into the mid-normal range — often 500-700 ng/dL from baselines below 300 ng/dL — while preserving or improving sperm count, motility, and morphology. This stands in sharp contrast to exogenous testosterone replacement therapy (TRT), which suppresses LH/FSH, shuts down intratesticular testosterone production, and typically drives sperm counts toward azoospermia within 3-6 months of use ([Anawalt, 2020]). Enclomiphene sits in an unusual regulatory limbo. Repros Therapeutics ran two successful Phase 3 trials (ZA-301 and ZA-302) in overweight men with secondary hypogonadism, demonstrating that once-daily 12.5 mg or 25 mg enclomiphene restored morning total testosterone while maintaining or increasing sperm concentration relative to both placebo and topical testosterone gel ([Kim et al., 2016]). Despite these results, the FDA declined to approve Androxal in 2015, citing concerns about the clinical meaningfulness of the primary endpoints and the absence of long-term cardiovascular outcomes data — concerns that parallel the broader regulatory pushback against all low-T treatment paradigms during the 2013-2016 era. Repros subsequently went bankrupt, and the molecule fell into a commercial gray zone: not FDA-approved, but sold widely through US telehealth clinics and compounding pharmacies under state physician supervision as an \"off-label\" or \"investigational\" testosterone tuning tool, particularly for men who want to avoid the fertility penalty of TRT. For bodybuilders, biohackers, and men pursuing testosterone tuning, enclomiphene has become a central pillar of the \"fertility-preserving\" and \"post-cycle therapy\" toolkits. It is used as (1) a monotherapy for men with secondary hypogonadism who want natural production rather than exogenous testosterone; (2) a post-cycle therapy (PCT) agent after anabolic steroid cycles to restart the HPG axis; (3) an adjunct or alternative to hCG for men on TRT who want to preserve testicular volume and fertility; and (4) a mild endogenous testosterone booster in men with borderline hypogonadism or age-related T decline. Its oral dosing, lack of injection requirement, favorable side effect profile relative to clomiphene itself, and fertility-preserving mechanism make it one of the more popular prescription-gray-market molecules in the men's health tuning space. This entry covers the full pharmacology, clinical evidence base, protocol considerations, and safety profile of enclomiphene citrate. It is intended for educational and research reference only — enclomiphene is a prescription drug in most jurisdictions, is NOT FDA-approved for any indication, and the decision to use it should involve a qualified physician who can order appropriate baseline and follow-up labs (total testosterone, free testosterone, estradiol, LH, FSH, SHBG, CBC, CMP, lipid panel, and semen analysis when fertility is a concern). Cross-reference this page with HCG, Gonadorelin, and Kisspeptin-10 for a complete picture of HPG axis modulation strategies.", "lastReviewed": "2026-05-04T11:35:15.65+00:00", "url": "https://www.bodyhackguide.co/compound/enclomiphene", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Enclomiphene", "alternateName": [ "Androxal" ], "description": "Enclomiphene citrate (ENC, Androxal, trans-clomiphene) is the pure trans-isomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM) developed originally by Repros Therapeutics for the treatment of secondary (hypogonadotropic) hypogonadism in men who want to preserve fertility. Where clomiphene citrate — the classical ovulation induction drug used in women since FDA approval in 1967 — is a 62:38 mixture of two geometric isomers (enclomiphene and zuclomiphene), enclomiphene is the short-acting antagonist component that carries virtually all of the therapeutically useful activity at the male hypothalamic-pituitary-gonadal (HPG) axis, while zuclomiphene is a long-half-life weak estrogen agonist that accumulates with chronic dosing and is blamed for much of clomiphene's off-target visual, mood, and gynecomastia-risk profile. In men, enclomiphene works by competitively blocking estradiol at estrogen receptor alpha (ERα) in the hypothalamus and pituitary. Negative feedback from circulating estradiol normally throttles gonadotropin-releasing hormone (GnRH) pulse generation; when enclomiphene occupies these receptors, the hypothalamus is \"blinded\" to estrogen, GnRH pulse frequency increases, the pituitary ramps up luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, and the testes respond by increasing endogenous testosterone production and spermatogenesis. The net clinical effect, in men with a functional HPG axis that is simply being under-driven (secondary hypogonadism), is a restoration of serum total testosterone into the mid-normal range — often 500-700 ng/dL from baselines below 300 ng/dL — while preserving or improving sperm count, motility, and morphology. This stands in sharp contrast to exogenous testosterone replacement therapy (TRT), which suppresses LH/FSH, shuts down intratesticular testosterone production, and typically drives sperm counts toward azoospermia within 3-6 months of use ([Anawalt, 2020]). Enclomiphene sits in an unusual regulatory limbo. Repros Therapeutics ran two successful Phase 3 trials (ZA-301 and ZA-302) in overweight men with secondary hypogonadism, demonstrating that once-daily 12.5 mg or 25 mg enclomiphene restored morning total testosterone while maintaining or increasing sperm concentration relative to both placebo and topical testosterone gel ([Kim et al., 2016]). Despite these results, the FDA declined to approve Androxal in 2015, citing concerns about the clinical meaningfulness of the primary endpoints and the absence of long-term cardiovascular outcomes data — concerns that parallel the broader regulatory pushback against all low-T treatment paradigms during the 2013-2016 era. Repros subsequently went bankrupt, and the molecule fell into a commercial gray zone: not FDA-approved, but sold widely through US telehealth clinics and compounding pharmacies under state physician supervision as an \"off-label\" or \"investigational\" testosterone tuning tool, particularly for men who want to avoid the fertility penalty of TRT. For bodybuilders, biohackers, and men pursuing testosterone tuning, enclomiphene has become a central pillar of the \"fertility-preserving\" and \"post-cycle therapy\" toolkits. It is used as (1) a monotherapy for men with secondary hypogonadism who want natural production rather than exogenous testosterone; (2) a post-cycle therapy (PCT) agent after anabolic steroid cycles to restart the HPG axis; (3) an adjunct or alternative to hCG for men on TRT who want to preserve testicular volume and fertility; and (4) a mild endogenous testosterone booster in men with borderline hypogonadism or age-related T decline. Its oral dosing, lack of injection requirement, favorable side effect profile relative to clomiphene itself, and fertility-preserving mechanism make it one of the more popular prescription-gray-market molecules in the men's health tuning space. This entry covers the full pharmacology, clinical evidence base, protocol considerations, and safety profile of enclomiphene citrate. It is intended for educational and research reference only — enclomiphene is a prescription drug in most jurisdictions, is NOT FDA-approved for any indication, and the decision to use it should involve a qualified physician who can order appropriate baseline and follow-up labs (total testosterone, free testosterone, estradiol, LH, FSH, SHBG, CBC, CMP, lipid panel, and semen analysis when fertility is a concern). Cross-reference this page with HCG, Gonadorelin, and Kisspeptin-10 for a complete picture of HPG axis modulation strategies.", "activeIngredient": "Enclomiphene", "administrationRoute": "Oral", "mechanismOfAction": "Primary Mechanism: Central Estrogen Receptor Antagonism Enclomiphene is a non-steroidal triphenylethylene with a molecular structure closely related to tamoxifen. Pharmacologically, it behaves as a mixed agonist/antagonist at estrogen receptors — a classical SERM profile — but with tissue-specific effects that differ markedly from tamoxifen, raloxifene, and other SERMs used in oncology and osteoporosis. At the hypothalamus and anterior pituitary, enclomiphene is a pure antagonist of estrogen receptor alpha (ERα). Under physiological conditions, circulating estradiol (E2) — most of which is produced in men via peripheral aromatization of testosterone in adipose tissue, liver, and skin — binds hypothalamic ERα and provides the major negative feedback signal that throttles GnRH pulse generation. This feedback loop is the biological governor on the HPG axis: as testosterone rises, aromatization generates estradiol, estradiol suppresses GnRH, and LH/FSH output falls, completing the circuit. When enclomiphene occupies hypothalamic ERα, estradiol can no longer exert this suppressive feedback. The hypothalamus perceives the estrogen signal as absent and responds by: Increasing GnRH pulse frequency: Kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus (AVPV) are derepressed, leading to more frequent GnRH bursts ([Dwyer et al., 2015]). Amplifying pituitary gonadotroph response: The pituitary becomes more sensitive to GnRH stimulation, producing larger LH and FSH pulses per GnRH input. Driving downstream testicular steroidogenesis: LH stimulates Leydig cells to synthesize testosterone from cholesterol via the classical steroidogenic pathway (StAR → P450scc → 3β-HSD → CYP17 → 17β-HSD). FSH supports Sertoli cell function and spermatogenesis. The net effect is an upward shift in the entire HPG axis set point — higher LH, higher FSH, and higher endogenous testosterone — without exogenous hormone administration. In clinical studies, typical LH increases range from 2-4x baseline, testosterone rises 50-100% from hypogonadal baseline, and the effects are maintained with chronic dosing because enclomiphene does not accumulate or cause tachyphylaxis ([Kaminetsky et al., 2013]). The Enclomiphene vs. Zuclomiphene Distinction Clomiphene citrate as prescribed for female ovulation induction is a racemic mixture of two stereoisomers: enclomiphene (the E-isomer, ~62%) and zuclomiphene (the Z-isomer, ~38%). These two molecules differ only in the geometric orientation around a single double bond, but their pharmacology is dramatically different: Enclomiphene is a short-acting ERα antagonist with a half-life of approximately 10 hours and complete clearance within 1-2 weeks of discontinuation. It does NOT accumulate with chronic dosing. Zuclomiphene is a long-acting weak ERα agonist with a half-life of 30+ days and measurable tissue concentrations for months after stopping chronic therapy. It DOES accumulate. This distinction matters enormously for men. When men take clomiphene long-term (the common \"clomid TRT\" approach), zuclomiphene gradually accumulates and begins to produce estrogen-agonist effects: visual disturbances (shimmering, floaters, rarely permanent retinal changes), mood destabilization (depression, anxiety, emotional lability), libido suppression paradoxically overriding the testosterone boost, and potentially long-term safety concerns from chronic ERα agonism in a male. Many of the complaints men have about \"clomid\" — the mood crashes, the vision issues, the libido problems — are attributable to zuclomiphene rather than to the antagonist component. Purifying enclomiphene removes zuclomiphene entirely. The result is a cleaner molecule that delivers the HPG axis stimulation without the off-target agonist burden. In head-to-head comparisons and clinical trials, enclomiphene produces substantially fewer mood, visual, and libido side effects than equipotent doses of clomiphene ([Wiehle et al., 2013]). This is the central pharmacological argument for using enclomiphene rather than clomiphene for extended HPG axis support. Fertility Preservation Pharmacology The clinical feature that sets enclomiphene apart from exogenous testosterone is its effect on spermatogenesis. Exogenous testosterone (whether injectable, topical, or oral) suppresses LH and FSH via direct pituitary negative feedback after peripheral conversion to estradiol and via direct androgen receptor feedback in the hypothalamus. This suppression drops intratesticular testosterone concentrations from their normal range of 500-1,000 ng/mL down to serum levels (5-10 ng/mL) — a 50-100x decrease. Since spermatogenesis requires extraordinarily high local testosterone concentrations (20-100x serum levels) to proceed through meiosis, the result is progressive oligospermia and, in most men, frank azoospermia within 3-6 months of consistent TRT use. Enclomiphene has the opposite effect. By stimulating rather than suppressing the HPG axis, it drives LH to support intratesticular testosterone production AND drives FSH to support Sertoli cell function and spermatogenesis directly. In men with baseline sub-fertility from secondary hypogonadism, enclomiphene typically improves sperm concentration, motility, and total motile count over 3-6 months of therapy ([Shabsigh et al., 2005] on clomiphene, with analogous data for enclomiphene). For men who want both symptomatic relief from low testosterone AND preservation of reproductive potential, this is a substantial advantage over TRT. Hepatic Metabolism and Pharmacokinetics Enclomiphene is orally bioavailable with peak plasma concentrations reached 4-8 hours after dosing. It undergoes extensive first-pass hepatic metabolism primarily via CYP2D6 and CYP3A4, with the main metabolite 4-hydroxy-enclomiphene retaining some antiestrogenic activity. Terminal elimination half-life is approximately 10 hours, which is why once-daily dosing is adequate for stable LH/FSH elevation. Excretion is primarily biliary/fecal, with minor urinary elimination. Because of CYP2D6 involvement, men who are CYP2D6 poor metabolizers (~7% of Caucasians, ~2% of East Asians) may experience higher plasma concentrations and more pronounced effects at standard doses. CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) may also elevate enclomiphene levels modestly, though clinically significant interactions are uncommon. CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) may reduce enclomiphene plasma levels and blunt response. Off-Target Receptor Activity Relative to tamoxifen and other SERMs, enclomiphene has minimal off-target activity at estrogen receptor beta (ERβ), androgen receptor, progesterone receptor, or glucocorticoid receptor. This relatively clean receptor profile contributes to its favorable tolerability in men, as most SERM-related side effects (hot flashes with tamoxifen, endometrial effects, bone density changes) arise from tissue-specific agonism at ERα in organs outside the HPG axis. Enclomiphene appears to be a near-pure HPG-axis modulator with minimal extra-axis activity at therapeutic doses.", "dosageForm": "capsule, liquid", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "How is enclomiphene different from clomiphene (Clomid)?", "acceptedAnswer": { "@type": "Answer", "text": "Clomiphene citrate (Clomid) is a 62:38 mixture of two stereoisomers: enclomiphene (the antagonist component) and zuclomiphene (a weak long-acting agonist). Enclomiphene is the purified antagonist alone, without zuclomiphene. Because zuclomiphene has a ~30-day half-life and accumulates with chronic dosing — producing most of clomiphene's mood, visual, and libido side effects — enclomiphene offers a cleaner tolerability profile while preserving the HPG axis stimulation that raises testosterone and LH/FSH (Wiehle et al., 2013)." } }, { "@type": "Question", "name": "Is enclomiphene FDA-approved?", "acceptedAnswer": { "@type": "Answer", "text": "No. Repros Therapeutics developed enclomiphene as 'Androxal' and completed successful Phase 3 trials, but the FDA issued a Complete Response Letter in 2015 declining approval and citing concerns about the clinical meaningfulness of primary endpoints and long-term cardiovascular safety data. Repros went bankrupt in 2017. Enclomiphene remains available through US compounding pharmacies with physician prescription as an 'off-label' or investigational medication, typically in men's health clinic settings." } }, { "@type": "Question", "name": "Does enclomiphene preserve fertility compared to testosterone replacement?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, this is the central clinical advantage. Exogenous testosterone suppresses LH and FSH, which dramatically reduces intratesticular testosterone and typically produces oligospermia or azoospermia within 3-6 months. Enclomiphene does the opposite — it stimulates LH/FSH, which drives both endogenous testosterone and spermatogenesis. In the Phase 3 Repros trials, enclomiphene groups maintained or improved sperm concentration while testosterone gel reduced it by approximately 40% (Kim et al., 2016)." } }, { "@type": "Question", "name": "What dose should I start with?", "acceptedAnswer": { "@type": "Answer", "text": "12.5 mg once daily is the standard starting dose for men with secondary hypogonadism. Most men reach adequate testosterone normalization (500-800 ng/dL) at this dose within 4-6 weeks. If response is partial after 8-12 weeks, increasing to 25 mg daily is reasonable. Higher doses (50+ mg) are generally reserved for short-course PCT applications and increase side effects substantially. Always obtain baseline labs and work with a physician." } }, { "@type": "Question", "name": "How long does it take to see results?", "acceptedAnswer": { "@type": "Answer", "text": "LH and FSH typically rise within the first week. Testosterone begins climbing noticeably by weeks 2-3 and approaches steady-state by weeks 6-8. Subjective symptom improvements (energy, libido, mood) often follow the hormonal changes with a 2-4 week lag — many men notice them by weeks 4-8. Sperm parameter changes, if present, take longer (3-6 months typically), reflecting the spermatogenesis cycle duration." } }, { "@type": "Question", "name": "Can I take enclomiphene long-term?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, enclomiphene can be continued indefinitely if tolerated and effective, based on clinical experience — there is no evidence of tachyphylaxis (loss of effect) over at least 12 months of continuous therapy, and it does not accumulate. Most long-term users settle on 12.5 mg daily or every-other-day maintenance dosing. Periodic reassessment (every 6-12 months) of ongoing need, response, and safety labs is recommended. Unlike TRT, stopping enclomiphene does not cause a dramatic hormonal crash." } }, { "@type": "Question", "name": "What side effects are most common?", "acceptedAnswer": { "@type": "Answer", "text": "The most common side effects are headache (8-12%), nausea (6-9%), hot flashes (5-8%), mild acne (4-7%), and mild mood changes (3-6%). Visual disturbances (shimmering, floaters) occur in less than 2% but should always prompt immediate discontinuation if noticed. Most side effects are mild, occur early in therapy, and resolve with continued use or dose adjustment. Enclomiphene is substantially better tolerated than clomiphene for equivalent HPG axis effect." } }, { "@type": "Question", "name": "Can enclomiphene be used for post-cycle therapy (PCT)?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, enclomiphene is a standard PCT agent, often used at 25 mg daily for 4 weeks followed by 12.5 mg daily for 2-4 weeks. Advanced PCT protocols combine hCG (to restart testicular responsiveness) with enclomiphene plus optionally tamoxifen. PCT effectiveness depends on cycle duration, compound used, and individual HPG axis resilience. Some men recover fully; others require extended support or ultimately transition to TRT. Always baseline and follow-up labs to confirm recovery." } }, { "@type": "Question", "name": "How does enclomiphene compare to hCG for preserving fertility on TRT?", "acceptedAnswer": { "@type": "Answer", "text": "Both can preserve testicular function and fertility alongside TRT, but mechanistically differ. hCG directly mimics LH and stimulates Leydig cells to produce intratesticular testosterone — bypassing the hypothalamus entirely. Enclomiphene blocks estrogen receptors centrally, increasing endogenous LH/FSH. On TRT, exogenous testosterone suppresses this central signaling, making enclomiphene less effective — hCG is the more conventional choice for TRT-alongside fertility preservation. Enclomiphene is best as a monotherapy (replacing TRT) rather than an adjunct." } }, { "@type": "Question", "name": "What labs should I monitor on enclomiphene?", "acceptedAnswer": { "@type": "Answer", "text": "Baseline: total testosterone, free testosterone, estradiol (sensitive LC/MS assay), LH, FSH, SHBG, prolactin, TSH, CBC, CMP, lipid panel, PSA if age >40, semen analysis if fertility relevant. Follow-up labs at 4-6 weeks after starting or dose changes, then every 3-6 months once stable, then every 6-12 months for long-term maintenance. Target ranges: total T 500-800 ng/dL, estradiol 20-40 pg/mL, hematocrit <52%, LH typically 2-4x baseline confirming mechanistic response." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```